Plain language summary: using matched patient data to evaluate omaveloxolone against the natural history of Friedreich ataxia

This Plain Language Summary of Publication article (PLSP) from Future Neurology describes omaveloxolone (Skyclarys^®), an approved medication for treating Friedreich ataxia (FA), a progressive inherited disorder affecting movement, coordination, and speech, in patients 16 years and older. The drug’s approval stems from the three-part MOXIe clinical trial program, particularly the MOXIe Part 2 study, which demonstrated that omaveloxolone effectively slowed disease progression compared to placebo over an 11-month period. While the medication does cause side effects, they were generally manageable, allowing most patients to continue treatment.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data’ and was published in ANNALS of Clinical and Translational Neurology.

Visit Wiley using the link to read the original article.

• lay summary
• Movement disorders
• natural history
• Neurodegenerative diseases
• plsp
• Propensity-matched analysis